Literature DB >> 22693232

A functional variation in CD55 increases the severity of 2009 pandemic H1N1 influenza A virus infection.

Jie Zhou1, Kelvin Kai-Wang To, Hui Dong, Zhong-Shan Cheng, Candy Choi-Yi Lau, Vincent K M Poon, Yan-Hui Fan, You-Qiang Song, Herman Tse, Kwok-Hung Chan, Bo-Jian Zheng, Guo-Ping Zhao, Kwok-Yung Yuen.   

Abstract

Infection due to 2009 pandemic H1N1 influenza A virus (A[H1N1]pdm09) is commonly manifested as mild infection but occasionally as severe pneumonia. We hypothesized that host genetic variations may contribute to disease severity. An initially small-scale genome-wide association study guided the selection of CD55 single-nucleotide polymorphisms in 425 Chinese patients with severe (n = 177) or mild (n = 248) disease. Carriers of rs2564978 genotype T/T were significantly associated with severe infection (odds ratio, 1.75; P = .011) under a recessive model, after adjustment for clinical confounders. An allele-specific effect on CD55 expression was revealed and ascribed to a promoter indel variation, which was in complete linkage disequilibrium with rs2564978. The promoter variant with deletion exhibited significantly lower transcriptional activity. We further demonstrated that CD55 can protect respiratory epithelial cells from complement attack. Additionally, A(H1N1)pdm09 infection promoted CD55 expression. In conclusion, CD55 polymorphisms are associated with severe A(H1N1)pdm09 infection. CD55 may exert a substantial impact on the disease severity of A(H1N1)pdm09 infection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22693232     DOI: 10.1093/infdis/jis378

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  44 in total

1.  Calculated risk: a new single-nucleotide polymorphism linked to severe influenza disease.

Authors:  Amie J Eisfeld; Yoshihiro Kawaoka
Journal:  Nat Med       Date:  2017-08-04       Impact factor: 53.440

Review 2.  Systems immunogenetics of vaccines.

Authors:  Michael Mooney; Shannon McWeeney; Rafick-Pierre Sékaly
Journal:  Semin Immunol       Date:  2013-07-22       Impact factor: 11.130

Review 3.  Complement regulation and kidney diseases: recent knowledge of the double-edged roles of complement activation in nephrology.

Authors:  Masashi Mizuno; Yasuhiro Suzuki; Yasuhiko Ito
Journal:  Clin Exp Nephrol       Date:  2017-03-24       Impact factor: 2.801

Review 4.  Influenza Pathogenesis: The Effect of Host Factors on Severity of Disease.

Authors:  Anshu P Gounder; Adrianus C M Boon
Journal:  J Immunol       Date:  2019-01-15       Impact factor: 5.422

Review 5.  Blood Groups in Infection and Host Susceptibility.

Authors:  Laura Cooling
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

Review 6.  A literature review of severity scores for adults with influenza or community-acquired pneumonia - implications for influenza vaccines and therapeutics.

Authors:  Katherine Adams; Mark W Tenforde; Shreya Chodisetty; Benjamin Lee; Eric J Chow; Wesley H Self; Manish M Patel
Journal:  Hum Vaccin Immunother       Date:  2021-11-10       Impact factor: 3.452

7.  Immunological considerations for developing antibody therapeutics for Influenza A.

Authors:  Po-Ying Chan-Hui; Kristine M Swiderek
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

Review 8.  The complement system in the airway epithelium: An overlooked host defense mechanism and therapeutic target?

Authors:  Hrishikesh S Kulkarni; M Kathryn Liszewski; Steven L Brody; John P Atkinson
Journal:  J Allergy Clin Immunol       Date:  2018-01-12       Impact factor: 10.793

Review 9.  Host genetic determinants of influenza pathogenicity.

Authors:  Tsai-Yu Lin; Abraham L Brass
Journal:  Curr Opin Virol       Date:  2013-08-08       Impact factor: 7.090

Review 10.  Host genetics of severe influenza: from mouse Mx1 to human IRF7.

Authors:  Michael J Ciancanelli; Laurent Abel; Shen-Ying Zhang; Jean-Laurent Casanova
Journal:  Curr Opin Immunol       Date:  2016-01-04       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.